The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human, phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of neoadjuvant use of ph-762 administered intratumorally in subjects with advanced melanoma.
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Severine Roy
No Relationships to Disclose
 
Benjamin Cuiffo
Employment - Phio Pharmaceuticals
Patents, Royalties, Other Intellectual Property - 2013 Co-inventor with Ruibao Ren, Brandeis University, Cancer Therapy #20130210890 2014 Co-inventor with Antoine Karnoub, BIDMC/HMS, Methods and Compositions For Use In Treatment FOXP2-Related Cancers. Application#61/975,207
 
James Cardia
Employment - Phio Pharmaceuticals
Stock and Other Ownership Interests - Phio Pharmaceuticals
Travel, Accommodations, Expenses - Phio Pharmaceuticals
 
Simon Paul Fricker
Employment - Phio Pharmaceuticals
Stock and Other Ownership Interests - Phio Pharmaceuticals
Consulting or Advisory Role - X4 Pharma